Skip to main content

Folotyn Disease Interactions

There are 2 disease interactions with Folotyn (pralatrexate).

Moderate

Pralatrexate (applies to Folotyn) liver impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

The safety, efficacy and pharmacokinetics of pralatrexate have not been evaluated in patients with hepatic impairment. Additionally, this drug can cause hepatotoxicity and liver function test abnormalities, which might require dose modification or discontinuation. Caution and monitoring is advised.

References

  1. (2009) "Product Information. Folotyn (pralatrexate)." Allos Therapeutics
Moderate

Pralatrexate (applies to Folotyn) renal impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Patients with moderate to severe renal function impairment may be at greater risk of toxicity due to increased exposure. Patients should be monitored for renal function and toxicity and dosage should be adjusted accordingly. For patients with severe renal impairment (GFR 15 to <30), the recommended dose of pralatrexate is 15 mg/m2. Avoid the use of pralatrexate in patients with ESRD undergoing dialysis, unless the potential effect justifies the potential risk.

References

  1. (2009) "Product Information. Folotyn (pralatrexate)." Allos Therapeutics

Folotyn drug interactions

There are 227 drug interactions with Folotyn (pralatrexate).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer